| Literature DB >> 24204983 |
Katarzyna Zwolińska1, Brygida Knysz, Jacek Gąsiorowski, Monika Pazgan-Simon, Andrzej Gładysz, Maciej Sobczyński, Egbert Piasecki.
Abstract
BACKGROUND: The human genome contains about 8% of endogenous retroviral sequences originated from germ cell infections by exogenous retroviruses during evolution. Most of those sequences are inactive because of accumulation of mutations but some of them are still capable to be transcribed and translated. The latter are insertionally polymorphic HERV-K113 and HERV-K115. It has been suggested that their presence and expression was connected with several human diseases. It is also believed that they could interfere with the replication cycle of exogenous retroviruses, including HIV.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24204983 PMCID: PMC3810129 DOI: 10.1371/journal.pone.0077820
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of studied groups.
| Groups | Control [HIV(−)] | EU [HIV(−)] | HIV(+) |
| Number of individuals [n] | 303 | 121 | 470 |
| Age range (mean) [years] | 5–71 (33.6) | 3–50 (30.5) | 0–59 (30.7) |
| Sex (female/male) [n (%)] | 159/144 (52.5/47.5%) | 41/80 (33.8/66.2%) | 158/312 (33.6/66.4%) |
| Homosexual exposure [n (%)] | NA | 2 (1.7%) | 35 (7.5%) |
| Heterosexual exposure [n (%)] | NA | 33 (27.2%) | 61 (13.0%) |
| Intravenous drug users [n (%)] | NA | 84 (69.4%) | 359 (76.4%) |
| Mother to child transmission [n (%)] | NA | 2 (1.7%) | 3 (0.6%) |
| Blood transfusion [n(%)] | NA | 0 (%) | 1 (0.2%) |
| Blood products [n(%)] | NA | 0 (%) | 1 (0.2%) |
| Unknown route of infection [n(%)] | NA | 0 (%) | 10 (2.1%) |
| HCV(+) [n (%)] | NT | 77 (63.6%) | 356 (75.7%) |
| HCV(−) [n (%)] | NT | 39 (32.2%) | 109 (23.2%) |
| No data for HCV co-infection [n (%)] | NT | 5 (4.2%) | 5 (1.1%) |
NA – not applicable; NT – not tested.
EU – exposed uninfected.
Primer sequences for HERV-K113 and HERV-K115 PCR.
| Detection | Primer | Sequences |
| HERV-K113 | K113-F1 | 5′ - GCA |
| K113-R1 | 5′ - CAT | |
| K113-LTR-F1 | 5′ - GG | |
| K113-LTR-R1 | 5′ - | |
| HERV-K115 | K115-F2 | 5′ - CCG |
| K115-R2 | 5′ - TCA | |
| K115-LTR-F2 | 5′ - GG | |
| K115-LTR-R2 | 5′ - TCT | |
| K115-PROV-R2 | 5′ - CTT |
Sequences from Moyes et al., 2005 [19].
Sequences from Burmeister et al., 2004 [26].
Figure 1Representative gels showing results of PCR HERV-K113 detection in this work.
1– homozygous negative individual (lack of HERV-K113 insertion); 2– heterozygous individual (retroviral insertion in one chromosome). An individual with HERV-K113 on both chromosomes was not detected. M – size standard; A – lines corresponding to the preintegration site (reaction A, 300 bp product); B – lines for HERV-K113 5′LTR and provirus fragment (reaction B, 1253 bp product); C – lines for HERV-K113 3′LTR (reaction C, 483 bp product).
Figure 2Agarose gels of PCR products of HERV-K115 detection.
1– homozygous negative individual (lack of HERV-K115 insertion); 2– heterozygous individual (retroviral insertion in one chromosome). No homozygous individual with retroviral HERV-K115 insertion on both chromosomes was detected. A – lines for preintegration site (reaction A, 557 bp product); B – lines for HERV-K115 5′LTR (reaction B, 380 bp product); C – lines corresponding to the provirus HERV-K115 fragment (reaction C, 1269 bp product); D – lines for HERV-K115 3′LTR (reaction D, 436 bp product).
Distribution of HERV-K113 and HERV-K115 in control group, exposed to HIV but uninfected (EU) and HIV-positive patients.
| Group | HERV-K113 | HERV-K115 | ||||||
| Lack of HERV-K113 [n] | HERV-K113 (+) [n] | HERV-K113(+) [%] | P-value | Lack of HERV-K115 [n] | HERV-K115 (+) [n] | HERV- K115(+) [%] | P-value | |
| Control (n = 303) | 267 | 36 | 11.88 | 0.546 | 279 | 24 | 7.92 | 0.773 |
| EU (n = 121) | 111 | 10 | 8.26 | 0.475 | 114 | 7 | 5.79 | 0.681 |
| HIV(+) (n = 470) | 409 | 61 | 12.98 | 0.208 | 436 | 34 | 7.23 | 0.658 |
Characteristics of HIV-infected and exposed uninfected patients included in analysis of HERV-K113 and HERV-K115 connection with HIV infection.
| Characteristics of studied groups | EU | HIV(+) | |||||||||
| n (%) | HERV-K113[n (%)] | No HERV-K113[n (%)] | HERV-K115[n (%)] | No HERV-K115[n (%)] | n (%) | HERV-K113[n (%)] | No HERV-K113[n (%)] | HERV-K115[n (%)] | No HERV-K115[n (%)] | ||
| Number of individuals | 114 (100.0) | 10 (8.8) | 104 (91.2) | 7 (6.1) | 104 (93.9) | 452 (100.0) | 57 (12.6) | 395 (87.4) | 33 (7.3) | 419 (92.7) | |
| Sex [n (%)] | female | 36 (31.6) | 4 (11.1) | 32 (88.9) | 1 (2.8) | 35 (97.2) | 151 (33.4) | 25 (16.6) | 126 (83.4) | 12 (7.9) | 139 (92.1) |
| male | 78 (68.4) | 6 (7.7) | 72 (92.3) | 6 (7.7) | 72 (92.3) | 301 (66.6) | 32 (10.6) | 169 (89.4) | 21 (7.0) | 280 (93.0) | |
| Mode of infection[n (%)] | homosexual | 2 (1.7) | 0 | 2 (100.0) | 0 | 2 (100.0) | 35 (7.7) | 4 (11.4) | 31 (88.6) | 5 (14.3) | 30 (85.7) |
| heterosexual | 28 (24.6) | 2 (7.1) | 26 (96.9) | 1 (3.6) | 27 (96.4) | 61 (13.5) | 11 (18.0) | 50 (82.0) | 4 (6.6) | 57 (93.4) | |
| Intravenous drugusers (IDU) | 84 (73.7) | 8 (9.5) | 76 (90.5) | 6 (7.0) | 78 (93.0) | 356 (78.8) | 42 (11.8) | 314 (88.2) | 24 (6.7) | 332 (93.3) | |
| HCV infection [n (%)] | − | 37 (32.5) | 3 (8.1) | 34 (91.9) | 2 (5.4) | 35 (94.6) | 98 (21.7) | 15 (15.3) | 83 (84.7) | 5 (5.1) | 93 (94.9) |
| + | 77 (67.5) | 7 (9.1) | 70 (90.9) | 5 (6.5) | 72 (93.5) | 354 (78.3) | 42 (11.9) | 312 (88.1) | 28 (7.9) | 326 (92.1) | |